Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:

Citi’s 2025 Global Healthcare Conference
Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET

Evercore 8th Annual Healthcare Conference 
Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET

The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Investor Contact: 
Eva Stroynowski
ir@apellis.com
617.938.6229


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.34
-3.07 (-1.31%)
AAPL  287.50
+1.31 (0.46%)
AMD  216.15
+0.91 (0.42%)
BAC  53.52
+0.33 (0.61%)
GOOG  318.23
+2.21 (0.70%)
META  643.47
-3.63 (-0.56%)
MSFT  477.99
-12.01 (-2.45%)
NVDA  180.57
-0.89 (-0.49%)
ORCL  202.85
+1.75 (0.87%)
TSLA  441.38
+12.14 (2.83%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.